Research programme: MRGPRX1 antagonists - Escient Pharmaceuticals
Latest Information Update: 04 Jun 2024
At a glance
- Originator Escient Pharmaceuticals
- Class Small molecules
- Mechanism of Action Mas related gene X1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 30 May 2024 Escient Pharmaceuticals has been acquired by Incyte Corporation
- 27 Jan 2023 Early research in Unspecified in USA (PO) before January 2023 (Escient Pharmaceuticals pipeline, January 2023)